Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2023-04-20 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
北京国枫（上海）律师事务所关于公司2022年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2022 Annual General Meeting (AGM) of Yunnan Watson Biotechnology Co., Ltd. It details the legality of the meeting's convening, attendance, voting procedures, and results. The document includes specific voting results on various agenda items such as the 2022 annual report, financial statements, profit distribution plan, and amendments to company rules. The document is not the annual report itself but a legal opinion on the AGM proceedings and voting outcomes. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results of the AGM. The document length (5130 characters) and content confirm it is not merely an announcement of a report but a detailed legal opinion on the AGM voting results. Therefore, the correct classification is DVA with high confidence.
2023-04-20 Chinese
2022年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2022 Annual General Meeting (AGM) of Yunnan Watson Biotechnology Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals including the 2022 Annual Report, financial reports, board reports, amendments to company rules, and capital changes. The document is not the Annual Report itself but the official announcement of the AGM resolutions and voting outcomes. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (5857 characters) and content confirm it is a full announcement of voting results rather than a brief report publication notice or a proxy statement. Therefore, the correct classification is DVA with high confidence.
2023-04-20 Chinese
关于获得新型冠状病毒变异株mRNA疫苗Ⅲ期效力临床试验期中分析主要结果的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the interim analysis results of a Phase III clinical trial for a COVID-19 mRNA vaccine. It provides detailed clinical trial results, safety data, and ongoing regulatory communication plans. The document is relatively short (964 characters) and is an announcement of clinical trial results rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is a specific announcement about clinical trial results and regulatory progress, which is best categorized under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2023-04-19 Chinese
关于2020年股票期权激励计划股票期权注销完成的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the completion of the cancellation of stock options under a 2020 stock option incentive plan. It details the board meeting decisions, the number of stock options cancelled, and references compliance with regulatory rules. The document is short (686 characters) and focuses on a specific corporate action related to stock options, not a financial report or earnings release. It is not a report itself but an announcement of a corporate event related to share-based compensation. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2023-04-18 Chinese
关于召开2022年年度股东大会的提示性公告
AGM Information Classification · 100% confidence The document is a detailed announcement regarding the convening of the 2022 Annual General Meeting (AGM) of Yunnan Watson Biotechnology Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be discussed, and registration details. The document does not contain the actual annual report or financial statements but rather serves as a notice and instructions for the AGM. The length is 4222 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2023-04-14 Chinese
关于首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the company's first share repurchase (buyback) plan and execution details. It includes specifics about the number of shares repurchased, prices, compliance with regulatory rules, and references to previous announcements about the repurchase plan. The document does not contain financial statements or earnings data but focuses on the share repurchase activity. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which reports on the company buying back its own shares.
2023-04-07 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.